Purpose of review
In recent years, our understanding of mitral regurgitation and its management has evolved substantially. In particular, as percutaneous mitral valve interventions have proven safe and effective, it has become possible to offer expanded therapeutic options to patients who are deemed inoperable or at high surgical risk. This review provides an overview of currently available transcatheter mitral valve interventions and summarizes recently published findings that may allow for better risk stratification, patient selection, and procedural safety and efficacy.
Recent findings
In the last 1–2 years, numerous studies have provided important insights that help to better characterize patients in clinical practice and to select them more optimally for specific interventional mitral valve procedures.
Summary
The evolution of percutaneous MV therapy has been substantial and extremely beneficial for patient care. Nonetheless, this is an area underdevelopment and newer or enhanced devices are likely to emerge in the future.